![All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma - European Journal of Cancer All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma - European Journal of Cancer](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/93a11084-1a8e-4735-85f5-cc8e760be88e/gr2_lrg.jpg)
All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma - European Journal of Cancer
![Frontiers | Real World Experience of Daratumumab: Evaluating Lymphopenia and Adverse Events in Multiple Myeloma Patients Frontiers | Real World Experience of Daratumumab: Evaluating Lymphopenia and Adverse Events in Multiple Myeloma Patients](https://www.frontiersin.org/files/MyHome%20Article%20Library/575168/575168_Thumb_400.jpg)
Frontiers | Real World Experience of Daratumumab: Evaluating Lymphopenia and Adverse Events in Multiple Myeloma Patients
Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of
![Monoclonal gammopathy of undetermined significance is associated with prostate cancer in a population-based cohort study | Scientific Reports Monoclonal gammopathy of undetermined significance is associated with prostate cancer in a population-based cohort study | Scientific Reports](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41598-021-98803-1/MediaObjects/41598_2021_98803_Fig1_HTML.png)
Monoclonal gammopathy of undetermined significance is associated with prostate cancer in a population-based cohort study | Scientific Reports
OAB-001 Potentiating T cell activity against multiple myeloma through SUMOylation inhibition Li Du1, Dennis Awuah1, Wei Liu2, En
Immune marker changes and risk of multiple myeloma: a nested case-control study using repeated pre-diagnostic blood samples | Haematologica
![Elevated IgM and abnormal free light chain ratio are increased in relatives from high-risk chronic lymphocytic leukemia pedigrees | Blood Cancer Journal Elevated IgM and abnormal free light chain ratio are increased in relatives from high-risk chronic lymphocytic leukemia pedigrees | Blood Cancer Journal](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41408-019-0186-8/MediaObjects/41408_2019_186_Fig1_HTML.png)
Elevated IgM and abnormal free light chain ratio are increased in relatives from high-risk chronic lymphocytic leukemia pedigrees | Blood Cancer Journal
![Immune marker changes and risk of multiple myeloma: a nested case-control study using repeated pre-diagnostic blood samples. - Abstract - Europe PMC Immune marker changes and risk of multiple myeloma: a nested case-control study using repeated pre-diagnostic blood samples. - Abstract - Europe PMC](https://europepmc.org/articles/PMC6959165/bin/1042456.fig2.jpg)